Study	Intervention name	Result		Unit of analysis	Time point	Type of assay	Population
		GMT (95% CI)	GMR (95% CI)
Heterologous schedule versus homologous schedule
Li 2021a	CoronaVac/Ad5	54.40 (37.90 to 78)	4.25 (2.63 to 6.86)	Not reported	14 days after 2nd dose	Cytopathic effect‐based microneutralization assay with a wild‐type SARS‐CoV‐2 virus strain	18–59 years
	CoronaVac	12.80  (9.30 to 17.50)